Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib Consolidation for MRD Eradication in CLL/SLL Treated With Venetoclax
NCT05317936Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2022
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pirtobrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Rate of undetectable minimal residual disease (MRD) in the peripheral blood. Started Nov 2022; status: terminated.
02
Drugs
pirtobrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05317936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05317936.